IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1126-1150 out of 1264.

<< < 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 > >>

Public Release: 21-May-2014
Nature Chemical Biology
Team validates potentially powerful new way to treat HER2-positive breast cancer
A CSHL-led research team reports that it has found a means of inhibiting a protein called PTP1B, whose expression is upregulated in HER2-positive breast cancer. They show that PTP1B plays a critical role in the development of tumors in which HER2 signaling is aberrant. Therefore, PTP1B may be a therapeutic target via which to treat the disease.
National Institutes of Health, Cold Spring Harbor Laboratory Cancer Center, American Diabetes Association

Contact: Peter Tarr
tarr@cshl.edu
516-367-5055
Cold Spring Harbor Laboratory

Public Release: 21-May-2014
JAMA Surgery
Most women who have double mastectomy don't need it, U-M study finds
About 70 percent of women who have both breasts removed following a breast cancer diagnosis do so despite a very low risk of facing cancer in the healthy breast, new research from the University of Michigan Comprehensive Cancer Center finds.
NIH/National Cancer Institute

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 21-May-2014
Journal of Translational Medicine
Cancer avatars for personalized medicine
Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have used computer simulations of cancer cells -- cancer avatars -- to identify drugs most likely to kill cancer cells isolated from patients' brain tumors.
National Brain Tumor Society, Barbara and Joseph Ajello Trust Fund, Tuttleman Family Foundation

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 21-May-2014
ASCO 50th Annual Meeting
EORTC to present cancer research results at ASCO 2014
The EORTC will present nine abstracts at the ASCO 2014 Annual Meeting which will be held May 30-June 3, 2014, in Chicago, Ill. Four abstracts will be presented in Oral Abstract Sessions, one in a Poster Highlights Session, and another four in General Poster Sessions.

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer

Public Release: 21-May-2014
JAMA Surgery
Study examines prophylactic double mastectomy following breast cancer diagnosis
Many women diagnosed with cancer in one breast consider, and eventually undergo, a contralateral prophylactic mastectomy to remove both breasts, although few of them have a clinically significant risk of developing cancer in both breasts.

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
The JAMA Network Journals

Public Release: 21-May-2014
Molecular Cancer Research
Molecule linked to aggressive pancreatic cancer offers potential clinical advances
Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient.
NIH/National Cancer Institute, Mayo Clinic SPORE in Pancreatic Cancer

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic

Public Release: 21-May-2014
International Journal of Cancer
The interruption of biological rhythms during chemotherapy worsen its side effects
Patients receiving chemical treatment for cancer often suffer fatigue and body weight loss, two of the most worrying effects of this therapy linked to the alteration of their circadian rhythms.

Contact: Press Office
info@agenciasinc.es
34-914-251-820
FECYT - Spanish Foundation for Science and Technology

Public Release: 21-May-2014
Molecular Cancer Therapeutics
Finnish researchers discovered a new anticancer compound
A team of research scientists from VTT Technical Research Centre of Finland, the University of Turku and the University of Eastern Finland has discovered a previously unknown Cent-1 molecule that kills cancer cells.

Contact: Marko Kallio
marko.kallio@vtt.fi
358-207-222-810
VTT Technical Research Centre of Finland

Public Release: 20-May-2014
JAMA
Genomic tumor testing to match lung cancer patients with targeted drugs transforms care
New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.
NIH/National Cancer Institute

Contact: Melissa Morgenweck
morgenwm@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center

Public Release: 20-May-2014
JAMA
Research identifies genetic alterations in lung cancers that help select treatment
Multiplexed testing of lung cancer tumors identified genetic alterations that were helpful in selecting targeted treatments. Patients that received matched therapy for lung cancer lived longer than patients who did not receive directed therapy, although randomized clinical trials are required to determine if this treatment strategy improves survival, according to a study in the May 21 issue of JAMA.

Contact: Melissa Morgenweck
morgenwm@mskcc.org
646-227-3633
The JAMA Network Journals

Public Release: 20-May-2014
American Society for Microbiology 114th General Meeting
More than two-thirds of healthy Americans are infected with human papilloma viruses
In what is believed to be the largest and most detailed genetic analysis of its kind, researchers at NYU Langone Medical Center and elsewhere have concluded that 69 percent of healthy American adults are infected with one or more of 109 strains of human papillomavirus.

Contact: David March
david.march@nyumc.org
212-404-3528
NYU Langone Medical Center / New York University School of Medicine

Public Release: 20-May-2014
American Urological Association Annual Meeting
Prolaris test predicts mortality risk in prostate cancer biopsy study
Data presented at AUA 2014 show the Prolaris test accurately predicted mortality risk from prostate cancer within 10 years in patients diagnosed with needle biopsy. The use of this test could improve treatment for patients at all risk levels based on each man's personal risk of disease progression. Prolaris has been proven to predict prostate cancer-specific disease progression in 11 clinical trials with more than 6,000 patients.

Contact: Ronald Rogers
rrogers@myriad.com
908-285-0248
Myriad Genetics, Inc.

Public Release: 20-May-2014
Molecular Cancer Therapeutics
Pine bark substance could be potent melanoma drug
A substance that comes from pine bark is a potential source for a new treatment of melanoma, according to Penn State College of Medicine researchers.
National Institutes of Health, Foreman Foundation for Melanoma Research, H.G. Barsumian, M.D. Memorial Fund

Contact: Matt Solovey
msolovey@hmc.psu.edu
717-531-8606
Penn State

Public Release: 20-May-2014
Nicotine and Tobacco Research
Students swayed by 'relaxing, fun' image of hookah smoking ignore health harms
Educational campaigns meant to dissuade college students from initiating hookah tobacco smoking may be more successful if they combat positive perceptions of hookah use as attractive and romantic, rather than focusing solely on the harmful components of hookah tobacco smoke, a new University of Pittsburgh School of Medicine study found.
NIH/National Cancer Institute, Steven Manners Memorial Fund

Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences

Public Release: 20-May-2014
Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Research explains action of drug that may slow aging and related disease
A proven approach to slow the aging process is dietary restriction, but new research helps explain the action of a drug that appears to mimic that process -- rapamycin. The advance moves science closer to a compound that might slow aging and reduce age-related disease.
National Institutes of Health

Contact: Viviana Perez
Viviana.perez@oregonstate.edu
541-737-9551
Oregon State University

Public Release: 20-May-2014
PLOS ONE
Study shows how streptococcal bacteria can be used to fight colon cancer
Researchers at Western University have shown how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer. By engineering a streptococcal bacterial toxin to attach itself to tumor cells, they are forcing the immune system to recognize and attack the cancer. The study found the engineered bacterial toxin could significantly reduce the size of human colon cancer tumors in mice, with a drastic reduction in the instances of metastasis.
Canadian Institutes of Health Research

Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario

Public Release: 19-May-2014
Annals of Internal Medicine
Study calls for revisiting cardiac screening guidelines for survivors of childhood cancer
One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending congestive heart failure finds improved health outcomes but suggests that less frequent screening than currently recommended may yield similar clinical benefit. The researchers, in a study published in the Annals of Internal Medicine, utilized a simulation-based model to estimate the long-term benefits associated with routine screening.
NIH/National Cancer Institute

Contact: Irene Sege
irene.sege@childrens.harvard.edu
617-919-3110
Dana-Farber Cancer Institute

Public Release: 19-May-2014
Annals of Internal Medicine
Tip sheet from Annals of Internal Medicine May 20, 2014
The May 20 issue of Annals of Internal Medicine includes articles titled: 'Task Force finds insufficient evidence to recommend for or against screening for suicide risk'; 'Vaccination during 'optimal window' is the key to saving lives and money in next flu pandemic'; and 'Two separate studies suggest that longer echocardiographic screening intervals for childhood cancer survivors effective, cost-effective for detecting heart issues.'

Contact: Megan Hanks
mhanks@acponline.org
215-351-2656
American College of Physicians

Public Release: 19-May-2014
Journal of Urology
Low risk prostate cancer not always low risk
Selection of men for active surveillance should be based not on the widely used conventional biopsy, but with a new, image-guided targeted prostate biopsy.
NIH/National Cancer Institute

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-794-2262
University of California - Los Angeles Health Sciences

Public Release: 19-May-2014
American Urological Association Annual Meeting
Robot-assisted prostate cancer surgery as safe but more expensive as open surgery in older men
Minimally invasive robot-assisted surgery, which has become the main choice for surgically removing cancerous prostate glands during recent years, is as safe as open surgery for Medicare patients over age 65. Those are the primary findings of a newly published nationwide patient survey that included participation by researchers at Henry Ford Hospital, a pioneer of robot-assisted radical prostatectomy.

Contact: Dwight Angell
dwight.angell@hfhs.org
313-850-3471
Henry Ford Health System

Public Release: 19-May-2014
Journal of Clinical Oncology
A call to arms in cancer research
The rapid growth in the Hispanic population in the US is not matched by growth in Hispanics participating in cancer clinical trials -- not even close. Given the health disparities experienced by this population it is crucial that cancer researchers include more Hispanics in their trials, and there are steps they can take to do so, in an analysis from the Cancer Therapy & Research Center at the UT Health Science Center San Antonio.
NIH/National Cancer Institute

Contact: Elizabeth Allen
allenea@uthscsa.edu
210-450-2020
University of Texas Health Science Center at San Antonio

Public Release: 19-May-2014
Angewandte Chemie
Scripps Research Institute chemists discover structure of cancer drug candidate
Chemists at The Scripps Research Institute have determined the correct structure of a highly promising anticancer compound approved by the US Food and Drug Administration for clinical trials in cancer patients. The new report, published this week by the international chemistry journal Angewandte Chemie, focuses on a compound called TIC10.
Skaggs Institute for Chemical Biology, Scripps Research Institute

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute

Public Release: 18-May-2014
American Society for Microbiology 114th General Meeting
Bacteria in mouth may diagnose pancreatic cancer
Patients with pancreatic cancer have a different and distinct profile of specific bacteria in their saliva compared to healthy controls and even patients with other cancers or pancreatic diseases, according to research presented today at the annual meeting of the American Society for Microbiology. These findings could form the basis for a test to diagnose the disease in its early stages.

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology

Public Release: 18-May-2014
Nano Letters
One small chip -- one giant leap forward for early cancer detection
An international team of researchers, led by ICFO- Institute of Photonic Sciences in Castelldefels, announce the successful development of a 'lab-on-a-chip' platform capable of detecting protein cancer markers in the blood using the very latest advances in plasmonics, nano-fabrication, microfluids and surface chemistry. The device is able to detect very low concentrations of protein cancer markers in blood, enabling diagnoses of the disease in its earliest stages.

Contact: Alina Hirschmann
alina.hirschmann@icfo.es
34-935-542-246
ICFO-The Institute of Photonic Sciences

Public Release: 16-May-2014
Journal of Clinical Investigation
JCI online ahead of print table of contents for May 16, 2014
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers published online, May 16, 2014 in the JCI: 'Targeting microbial translocation attenuates SIV-mediated inflammation,' 'Estrogen underlies sex-specific responses to sildenafil,' 'Vaccine-induced cell population inhibits SIV vaccine efficacy,' 'Enhancing efficacy of the cancer drug cetuximab,' 'Beta-catenin-regulated myeloid cell adhesion and migration determine wound healing,' 'Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression,' and more.

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Showing releases 1126-1150 out of 1264.

<< < 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 > >>

  Search News Releases

     

 

EurekAlert!